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Open access under CC BYA randomized, controlled, open-label, parallel-group, single-center study to determine biomarkers of
exposure to twelve selected harmful and potentially harmful constituents (HPHCs) in cigarette smoke
and urinary excretion of mutagenic material in 128 male and female Japanese subjects smokingMarlboro
cigarettes (6 mg tar, 0.5 mg nicotine, and 7.0 mg CO) at baseline. Subjects were randomized to continue
smoking Marlboro cigarettes, or switch to the Electrically Heated Cigarette Smoking System (EHCSS) and
smoke either the EHCSS-K6 (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO) or the EHCSS-K3 (3 mg tar, 0.2 mg
nicotine, and 0.6 mg CO) cigarette, or switch to smoking Lark One cigarettes (1 mg tar, 0.1 mg nicotine,
and 2.0 mg CO), or to no-smoking. The mean decreases from baseline to Day 8 were statistically signif-
icant (p 6 0.05) for all cigarette smoke HPHC including CO (the primary objective) and excretion of muta-
genic material in the EHCSS-K6 (range: 14.6% to 75.6%) and EHCSS-K3 (range: 9.8% to 73.0%)
groups. Statistically signiﬁcant reductions (all p 6 0.05) in exposure to ten cigarette smoke HPHC (range:
5.9% to 34.6%), but not urinary mutagenicity, were observed in the Lark One group. The largest mean
reductions in exposure to HPHC (all p 6 0.01 level) occurred in the no-smoking group (range: 13.7% to
97.6%).
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
There is overwhelming medical and scientiﬁc consensus that
cigarette smoking causes lung cancer, heart disease, emphysema,
and other serious diseases in smokers (US Department of Health
and Human Services, 2010; Ministry of Health, Labour andWelfare,
2008). In the US the Family Smoking Prevention and Tobacco Con-
trol Act (FSPTCA) (Family Smoking Prevention and Tobacco Control
Act, 2009) has empowered the Food and Drug Administration
(FDA) to evaluate and regulate modiﬁed risk tobacco products
(MRTPs) (Deyton et al., 2010). The FDA, in consultation with the
Institute of Medicine (IOM), has also been charged to issue guid-
ance and regulations on the scientiﬁc evidence required for the
assessment and ongoing review of MRTPs (Food and Drug Admin-
istration, 2012; Institute of Medicine, 2012).
The electrically heated cigarette smoking system (EHCSS) and
EHCSS cigarette produces reduced levels of a wide range of toxico-
logically important cigarette smoke HPHC and signiﬁcantly lowers
the biological activity of mainstream smoke compared to conven-icker).
-NC-ND license.tional lit-end cigarettes in laboratory-based test systems (Werley
et al., 2008; Zenzen et al., 2012). Electrical heating of the tobacco
reduces pyrolysis, and produces smoke that contains lower
amounts of most cigarette smoke HPHC. The current third-genera-
tion EHCSS series-K puff-activated electrical heater can only be
used to smoke either non-menthol or mentholated series-K ciga-
rettes. A more efﬁcient ﬁlter is used in the EHCSS-K3 non-menthol
cigarette resulting in reduced delivery of cigarette smoke HPHC
compared to the EHCSS-K6 non-menthol cigarette when tested
according to International Organization for Standardization (ISO)
methods.
The current communication, the third in a series of ﬁve clinical
evaluations of the EHCSS (Martin Leroy et al., 2012; Tricker et al.,
2012a,b,c), reports a randomized, controlled, open-label, parallel-
group, single-center study. Subjects normally smoking Marlboro
non-menthol cigarettes with a 6 mg tar and 0.5 mg nicotine deliv-
ery (M6J) at baseline were randomized to continue smoking the
M6J cigarette, or switched to using the EHCSS series-K heater to
smoke either the EHCSS-K3 or the EHCSS-K3 cigarette, or switch
to smoking the Lark One cigarette (Lark1), or switch to no-smoking,
for a duration of 8 days. None of the study cigarettes contained
menthol as a tobacco additive and all cigarettes were commercially
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examine changes in selected tobacco-speciﬁc and tobacco-related
biomarkers of exposure to HPHC known to be present in the
gas–vapor phase (1,3-butadiene, acrolein, benzene, CO, and croton-
aldehyde) and the particulate phase (2-naphthylamine, 4-aminobi-
phenyl, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [NNK],
acrylamide, nicotine, pyrene, and o-toluidine) of mainstream ciga-
rette smoke. The use of suitable biomarkers of exposure to these
HPHC offers one potential method to assess whether differences
in exposure to cigarette smoke HPHC has occurred in smokers
switching from one cigarette to another (Shields, 2002; Hecht,
2003; Hatsukami et al., 2005). Excretion of mutagenic material in
urine was also measured.
The primary objective of the study was to compare exposure to
CO, determined as carboxyhemoglobin concentration in blood at
17:00 h (COHb17:00), between the study groups on Day 8. Exposure
to CO was selected as the primary objective based on the reduction
of CO in mainstream smoke compared to conventional cigarettes
(Werley et al., 2008; Zenzen et al., 2012) and the previous observa-
tion that COHb is reduced in smokers after switching to the EHCSS
(Frost-Pineda et al., 2008a,b).2. Materials and methods
2.1. Subjects
Adult male and female Japanese smokers (19–50 years of age)
with acceptable health conditions who had smoked 10–30 ciga-
rettes per day (CPD) were recruited. Subjects were to have smoked
theMarlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and
7.0 mg CO) as their exclusive brand for at least 2 weeks prior to
study conﬁnement. All subjects signed an informed consent form
prior to screening procedures. Subjects were compensated for
study participation and were free to withdraw from the study at
any time. Screening was performed within 4 weeks prior to in-
clinic study conﬁnement and included medical history, physical
examination, vital signs, electrocardiogram (ECG), pulmonary
function tests, clinical laboratory tests, urine pregnancy test, blood
COHb, and the Fagerström Test for Nicotine Dependence (FTND)
(Heatherton et al., 1991). Women of childbearing potential who
used a reliable method of contraception were considered eligible
for study inclusion; pregnant or lactating women were excluded.
Other exclusion criteria included clinically signiﬁcant disease, alco-
hol or drug abuse, <1.5% COHb (suggestive of being a non-smoker),
<12.5 g/dl hemoglobin or <38% hematocrit, body mass index
(BMI) 6 17.6 andP26.4 kg/m2, a positive test for human immuno-
deﬁciency virus (HIV) or hepatitis, and the use of a nicotine-con-
taining product other than cigarettes within 3 months prior to
screening. The use of any medication with the exceptions of hor-
monal contraceptives for female subjects and occasional use of
paracetamol (up to 1 g/day) to treat headache was prohibited in
the week before the study.2.2. Cigarette products
Conventional cigarette (CC) brands were selected to include a
leading market share cigarette on the Japanese market of similar
ISO tar and nicotine yields to the EHCSS-K6 and a representative
CC with a low ISO tar and nicotine yield. Both cigarettes also had
a similar tobacco blend to that used in the EHCSS test cigarettes.
Study cigarettes were analyzed for tar and nicotine according to
ISO methods. All study cigarettes were conditioned according to
ISO standard 3402 (International Organization for Standardization,
1991). Conventional cigarettes were smoked on a smoking ma-
chine according to ISO standard 3308 (International Organizationfor Standardization, 2000a). Tar, nicotine and CO were determined
according to ISO standards 4387, 10315, and 8454, respectively
(International Organization for Standardization, 2000b,c; Interna-
tional Organization for Standardization, 1995). These methods
are essentially similar to methods used by the Tobacco Institute
of Japan for declaration of tar and nicotine levels on cigarette pack-
aging. Mainstream smoke from EHCSS cigarettes was generated on
a modiﬁed smoking machine with a carousel adapted to use the
EHCSS series-K lighter. The EHCSS smoke generation conformed
to ISO standard 3308; some slight technical deviations were re-
quired. The ISO yields as declared on the cigarette packaging were
as follows: Marlboro (M6J; 6 mg tar, 0.5 mg nicotine, and 7.0 mg
CO), Lark One (Lark1; 1 mg tar, 0.1 mg nicotine, and 2.0 mg CO),
EHCSS-K6 (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO), and EHCSS-
K3 (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO).
2.3. Study design and conduct
All recruited subjects (N = 131; 91 males and 40 females) com-
pleted a 7-day diary prior to admission to the clinic during the
morning on Day 2 (Fig. 1). The median daily cigarette consump-
tion according to the 7-day diary was used to individually deter-
mine the maximum number of cigarettes that the subject could
smoke per day during the study (120% of the median, rounded to
the nearest whole number, with a maximum of 30 CPD if the med-
ian was greater than 25 CPD). All subjects were conﬁned to the
clinic from Day 2 to Day 9 under medical supervision. On Day
2, the eligibility for study inclusion was re-conﬁrmed. Assess-
ments included COHb (13:00), vital signs (15:00), and a physical
examination. On Day 1, vital signs and a 12-lead ECG were mea-
sured (07:00) and blood samples drawn for clinical laboratory
tests. On Day 0 (baseline), assessments included determination of
biomarkers of exposure in a 24-h urine sample (combined urine
voids starting at 07:00), vital signs (07:00), COHb (COHb07:00 and
COHb17:00; 07:00 and 17:00), plasma cotinine and nicotine (COT-
P17:00 and NIC-P17:00; 17:00). One hundred and twenty-eight sub-
jects (89 males and 39 females) were randomized into 1 of 5 par-
allel groups (EHCSS-K3, EHCSS-K6, M6J, Lark1, and no-smoking;
N = 28 per smoking group, and N = 16 in the no-smoking group)
using a stratiﬁcation based on gender and median daily cigarette
consumption (10–19 and 20–30 CPD). On randomization, subjects
continuing to smoke conventional cigarettes (M6J or Lark1) were
‘blind’ to the identity of the test cigarettes. Non-randomized
subjects were released from the study center after completing all
scheduled assessments. Subjects withdrawing from the study or
those removed by the Investigator after baseline were not
replaced. From Day 1 through Day 8, subjects participated in their
assigned study groups. Assessments included determination of
biomarkers of exposure in 24-h urine samples (starting at 07:00),
vital signs (07:00), COHb07:00 (Days 1, 5, and 8), COHb17:00, COT-
P17:00, and NIC-P17:00. On Day 9 (end of study), vital signs, ECG, clin-
ical laboratory tests, and a physical examination were performed at
07:00 prior to release of subjects from the study center.
On Day 2 through Day 0, subjects were only permitted to
smoke M6J cigarettes. On Day 1 through Day 8 subjects smoked
their randomized study cigarette or stopped smoking if they were
randomized to the no-smoking group. M6J and Lark1 cigarettes
were lit using a blue ﬂame gas lighter. EHCSS-K3 and EHCSS-K6
cigarettes were smoked using the EHCSS series-K heater (Werley
et al., 2008). To ensure study integrity, all M6J and Lark1 cigarette
butts and smoked EHCSS-K3 and EHCSS-K6 cigarettes were
collected. Smoking was permitted only at designated smoking
times from 07:30 to 23:00 and subjects were neither encouraged
nor forced to smoke at any time during the study. All subjects re-
ceived a dietician-designed low-mutagen diet (Smith et al.,
1996). Identical menus were served on Days 1, 4 and 7 (days
EHCSS-K6 (N = 28) 
M6J 
(N = 128) 
Subject  
recruitment 
and 
medical  
screening 
Controlled smoking (9 days) 
EHCSS-K3 (N = 28) 
M6J (N = 28) 
Lark1 (N = 28) 
No-smoking (N = 16) 
Day 0 Days 1 to 8 
Biomarker assessments (blood and 24-h urine) 
Fig. 1. Schedule of study events. Footnote: On Day 0 (baseline) all subjects smoked the M6J cigarette prior to randomization into the ﬁve study groups. All cigarettes
described in Table 2.
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and 8 (days on which urinary mutagenicity was determined).
Water was permitted ad libitum, and consumption of caffeinated
beverages was not permitted.
The study was conducted at the Osaka Clinical Research
Organisation for Medicine (OCROM) Clinic, 4-12-11 Kasuga,
Suita-shi, Osaka 565-0853, Japan, and was conducted in
compliance with the ethical principles that have their origin in
the Declaration of Helsinki and that are consistent with Good
Clinical Practice (1964, and regularly amended; 1996) and Good
Clinical Practice Guidelines issued by the Japanese Ministry of
Health, Labour and Welfare (2004). The study was approved by
the OCROM Clinic Institutional Review Board, Osaka, Japan.2.4. Bioanalytical methodology
All urine voided in a 24-h period on study Day 0 through Day 8
was stored refrigerated at 2–8 C on the day of urine collection, to-
tal urine volume measured, and aliquots stored frozen at 20 C
pending biomarker analysis (Table 1). Tobacco-speciﬁc and tobac-
co-related biomarkers of exposure (Hecht, 2003; Lindner et al.,
2011; Schorp et al., 2012) were determined for the following
HPHC: (i) tobacco-speciﬁc biomarkers of exposure were deter-
mined for nicotine (Benowitz et al., 1994) and NNK (Carmella
et al., 2003), and (ii) tobacco-related biomarkers of exposure were
selected for 1,3-butadiene (van Sittert et al., 2000), 2-naphthyl-
amine (Riedel et al., 2006), 4-aminobiphenyl (Riedel et al., 2006),
acrolein (Mascher et al., 2001), acrylamide (Urban et al., 2006),
benzene (Medeiros et al., 1997), crotonaldehyde (Scherer et al.,
2007), pyrene (Strickland et al., 1996), and o-toluidine (Riedel
et al., 2006). All biomarkers were determined by liquid chromatog-
raphy–tandemmass spectrometry (LC–MS/MS) using methods val-
idated according to Food and Drug Administration criteria (Food
and Drug Administration, 2001). Some of the instrumentation used
(Table 1) may differ to that reported in the original methods.
Excretion of mutagenic material towards Salmonella typhimurium
YG1024 was determined using the Ames plate incorporation assay
(Einistö et al., 1990). Blood samples for determination of COHb
were drawn in sodium heparin vacutainer tubes and measured
on the day of collection by spectrophotometry (Pojer et al.,
1984). Blood samples for determination of nicotine metabolites
(COT-P and NIC-P) were drawn in sodium heparin vacutainer tubesand plasma stored at 20 C prior to analysis by LC–MS/MS (Beno-
witz, 1988).
All laboratory analyses were performed in a blinded manner
without knowledge of the study group assignment.
2.5. Data analysis
For data summary and statistical analysis, biomarker values be-
low the lower limit of quantiﬁcation (LLOQ) were set to LLOQ/2.
Exposure to nicotine was analyzed based on nicotine equivalents
(NEq) excretion, calculated as the molar sum of the concentrations
of nicotine and the ﬁve major nicotine metabolites (nicotine–glu-
curonide, free cotinine, cotinine–glucuronide, free trans-30-
hydroxycotinine, and trans-30-hydroxycotinine–glucuronide) in ur-
ine. Urine samples showing signs of cytotoxicity and/or precipitate
were excluded from the mutagenicity analysis.
Descriptive statistics were derived for each biomarker and their
changes from baseline by study group and day. Baseline compara-
bility of different study groups was examined using the non-para-
metric Kruskal–Wallis test. Changes in biomarker values (from
baseline to Day 8) within each study group were analyzed for addi-
tional descriptive purpose by paired sample t-tests (two-sided,
a = 0.05).
Differences in absolute end-of-study (Day 8) values between
EHCSS-K3 and the two conventional cigarette groups, M6J and
Lark1, were analyzed by analysis of covariance (ANCOVA) with fac-
tors study group, gender, and daily cigarette consumption and the
baseline value as covariate. Interaction terms for study group 
gender and study group  daily cigarette consumption were in-
cluded into the model if signiﬁcant interactions (at the a = 0.1 le-
vel) were evident. If the global test showed a signiﬁcant
difference between study groups (at the a = 0.05 level), pairwise
comparisons of EHCSS-K3 and M6J and Lark1, respectively, were
performed according to Dunnett (one-sided at a = 0.025). Identical
analysis was also performed to compare EHCSS-K6 with M6J and
Lark1.
Changes in urinary mutagenicity were analyzed using square
root-transformed data since the data were not normally distrib-
uted. Additionally, urinary biomarkers adjusted for creatinine
excretion, and NEq adjusted by the individual number of cigarettes
smoked per day (NEqNCig) were analyzed.
All statistical analyses were of an exploratory nature. Therefore,
apart from adjustment for the pairwise comparisons for each
Table 1
Summary of smoke constituent biomarkers of exposure, and bioanalytical methods.
Smoke constituent Biomarker Matrix Analytical methoda Lower limit of quantiﬁcation
1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA) Urine LC–MS/MS 100 pg/ml
2-Naphthylamine 2-Naphthylamine (2-NA) Urine LC–MS/MS 5.0 pg/ml
4-Aminobiphenyl 4-Aminobiphenyl (4-ABP) Urine LC–MS/MS 5.0 pg/ml
Acrolein 3-Hydroxypropyl mercapturic acid (3-HPMA) Urine LC–MS/MS 35 ng/ml
Acrylamide Acrylamide mercapturic acid (AAMA) Urine LC–MS/MS 2.5 ng/ml
Glycidamide mercapturic acid (GAMA) Urine LC–MS/MS 1.5 ng/ml
Benzene S-Phenyl mercapturic acid (S-PMA) Urine LC–MS/MS 20 pg/ml
Carbon monoxide Carboxyhemoglobin (COHb) Blood Spectrophotometry 0.3% Saturation
Crotonaldehyde 3-Hydroxy-1-methylpropyl mercapturic acid (3-HMPMA) Urine LC–MS/MS 92 pg/ml
Nicotine Cotinine (COT-P) Plasma LC–MS/MS 10 ng/ml
Nicotine (NIC-P) Plasma LC–MS/MS 1.0 ng/ml
Nicotine equivalents (NEq)c Urine LC–MS/MS NAf
NNKb Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)d Urine LC–MS/MS 5.0 pg/ml
Pyrene Total 1-hydroxypyrene (1-OHP)e Urine LC–MS/MS 10 pg/ml
o-Toluidine o-Toluidine (o-TOL) Urine LC–MS/MS 25 pg/ml
Mutagens Salmonella mutagenicity (YG1024 with S9) Urine Ames plate incorporation assay NA
a LC–MS/MS, liquid chromatography–tandem mass spectrometry.
b NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
c Nicotine equivalents (NEq) were determined as the molar sum of nicotine, cotinine, and trans-30-hydroxycotinine plus their respective glucuronide conjugates.
d Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) was determined as the molar sum of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its o-glucuronide
conjugate.
e Total 1-hydroxypyrene (1-OHP) was determined as the molar sum of 1-hydroxypyrene and its glucuronide and sulfate conjugates.
f NA, not applicable.
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level, no further adjustment for multiplicity was performed.
All statistical analyses were performed using SAS Version 8.2.
Unless otherwise stated, all analyses are reported for the intent-to-
treat population (ITT) which included all subjects who had a valid
assessment of the primary biomarker variables at baseline and at
least one post-baseline assessment (subjects in the smoking
groups must have smoked at least one study cigarette).
2.6. Determination of sample size
It was assumed that Lark1 smokers would have a comparable
concentration of COHb at 17:00 (COHb17:00) to that seen in a pre-
vious study (Tricker et al., 2012b) in which subjects who smoked
Lark1 cigarettes for 8 days had an average concentration of
3.63 ± 1.85% COHb17:00 on Day 8, while the concentration in the
EHCSS-K3 group was at least 40% lower. For a two-sample t-test
of a mean difference (pairwise comparison of Lark1 with EHCSS-
K3 and EHCSS-K6) with a normal one-sided signiﬁcance level of
a = 0.05 and assuming a common standard deviation of r = 1.8, a
sample size of 28 subjects per group was required to obtain a test
power of at least 90% (1  b = 0.9) to detect a 40% difference in
mean COHb17:00 concentrations between the Lark1 group (2.18%)
and the EHCSS-K3 and EHCSS-K6 groups (3.63%). A no-smoking
group was included to show the maximal reduction in COHb17:00
on smoking cessation. A size of 16 subjects in the no-smoking
group was chosen for practical reasons.
2.7. Adverse events, medical history, and concomitant medication
Adverse events (AEs) and medical history were coded using the
Medical Dictionary for Regulatory Activities (MedDRA Version 8.0).
Medication was coded according to the World Health Organization
(WHO) Drug Reference List (Version 1.03).
3. Results
3.1. Demographic and other baseline characteristics
The ITT population consisted of 128 subjects (89 males and 39
females). Demographic characteristics by study group are summa-rized in Table 2. All subjects were of Japanese origin. There were
about twice as many men as women in each study group. The indi-
vidual study groups were balanced with respect to gender and
smoking category (10–19 and 20–30 CPD) ratios. The mean subject
age was 23.5 ± 2.4 years (range: 21–31 years) and mean body mass
index (BMI) was 20.8 ± 2.1 kg/m2 (range: 17.6–26.3 kg/m2). There
were no signiﬁcant differences between males and females with
respect to age, BMI, duration of smoking, average daily cigarette
consumption, and demographic variables in the different study
groups. The majority of subjects (N = 116, 90.6%) had smoked for
<10 years. There was no signiﬁcant difference in the FTND score
between male (mean score: 3.7 ± 1.6) and female (mean score:
4.4 ± 1.9) subjects. FTND scores were lower for smokers of 10–19
CPD (mean score: 3.3 ± 1.8) compared to smokers of 20–30 CPD
(mean score: 4.5 ± 1.5).
Clinical and laboratory assessments at baseline did not reveal
any clinically signiﬁcant abnormal values in the randomized sub-
jects. After randomization, 126 subjects (89 males and 39 females)
completed the study; 2 female subjects withdrew for personal
reasons.
3.2. Cigarette consumption
The mean number of CPD at baseline was similar among the 5
study groups (Table 3). On Day 1, the ﬁrst day when subjects
smoked their respective randomized study cigarette, the mean
number of cigarettes smoked was lower in the four smoking
groups. On Day 8, the average cigarette consumption in all groups
was comparable, although slightly higher in the EHCSS-K3 and
EHCSS-K6 groups than at baseline, and slightly lower in the M6J
group than at baseline. The difference in average cigarette con-
sumption between groups was not signiﬁcant. Despite the fact that
subjects were allowed to increase their cigarette consumption by
120% from baseline, no signiﬁcant trends in increased cigarette
consumption were observed after randomization to the EHCSS-
K6, EHCSS-K3 and Lark1 study groups.
3.3. Biomarkers of exposure
There were no statistically signiﬁcant differences in COHb17:00,
the primary study objective, and other measures of COHb between
Table 2
Demographic summary by study group.
Variable and statistics Study groupa
M6J EHCSS-K6 EHCSS-K3 Lark1 No-smoking
Number (N) 28 28 28 28 16
Age (mean ± SD) 23.5 ± 2.2 23.4 ± 2.4 23.7 ± 2.6 23.3 ± 2.4 23.9 ± 2.3
Gender (N, % of total)
Female 8 (28.6%) 9 (32.1%) 7 (25.0%) 9 (32.1%) 6 (37.5%)
Male 20 (71.4%) 19 (67.9%) 21 (75.0%) 19 (67.9%) 10 (62.5%)
BMIb (kg/m2, mean ± SD) 20.75 ± 2.25 20.90 ± 1.57 20.68 ± 1.99 20.46 ± 2.33 21.77 ± 2.54
Duration of smoking (N years, % of total)
3 Years or less 9 (32.1%) 8 (28.6%) 8 (28.6%) 14 (50.0%) 4 (25.0%)
4–9 Years 17 (60.7%) 15 (53.6%) 17 (60.7%) 13 (46.4%) 11 (68.8%)
10–15 Years 2 (7.1%) 5 (17.9%) 3 (10.7%) 1 (3.6%) 1 (6.3%)
16 Years or more 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Fagerström Scorec (mean ± SD) 4.1 (1.8) 3.6 (1.8) 3.9 (1.2) 4.1 (2.1) 3.9 (1.7)
a Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 series-K non-menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); EHCSS-K6, EHCSS
series-K heater and EHCSS-K6 series-K non-menthol cigarette (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO); M6J,Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and
7.0 mg CO); Lark1, Lark One non-menthol cigarette (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO); and No-smoking, smoking cessation group.
b BMI, body mass index.
c The Fagerström Score was calculated as published (Heatherton et al., 1991).
Table 3
Daily cigarette consumption by group and study day.
Study daya Study groupb
M6J EHCSS-K6 EHCSS-K3 Lark1 No-smoking
Day 0 (Baseline) 17.6 ± 4.6 17.7 ± 5.1 17.2 ± 4.1 17.1 ± 4.4 17.2 ± 4.5
Day 1 16.8 ± 3.7 16.5 ± 5.0 16.4 ± 3.7 16.5 ± 4.5 0
Day 2 16.5 ± 3.6 16.9 ± 5.3 16.2 ± 3.9 16.4 ± 4.6 0
Day 3 16.7 ± 3.6 17.3 ± 5.4 16.7 ± 4.4 16.8 ± 5.0 0
Day 4 16.6 ± 3.7 17.5 ± 5.4 16.6 ± 3.4 16.8 ± 5.0 0
Day 5 16.7 ± 3.8 17.2 ± 5.4 16.9 ± 3.8 16.4 ± 4.5 0
Day 6 16.4 ± 3.6 17.3 ± 5.3 16.8 ± 3.7 16.6 ± 4.5 0
Day 7 16.8 ± 3.6 17.6 ± 5.6 17.1 ± 3.8 16.5 ± 4.5 0
Day 8 17.2 ± 3.8 18.0 ± 5.3 18.1 ± 4.0 17.1 ± 4.8 0
a At Day 0 (baseline) all groups smoked the M6J cigarette. On Day 1 through Day
8 groups smoked their randomized study cigarette or stopped smoking.
b Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 series-
K non-menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); EHCSS-K6,
EHCSS series-K heater and EHCSS-K6 series-K non-menthol cigarette (5 mg tar,
0.3 mg nicotine, and 0.6 mg CO); M6J, Marlboro non-menthol cigarette (6 mg tar,
0.5 mg nicotine, and 7.0 mg CO); Lark1, Lark One non-menthol cigarette (1 mg tar,
0.1 mg nicotine, and 2.0 mg CO); and No-smoking, smoking cessation group.
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biomarkers of exposure to 2-naphthylamine, 4-aminobiphenyl,
acrolein, acrylamide, benzene, crotonaldehyde, nicotine (deter-
mined NEq, COT-P17:00 and NIC-P17:00), NNK, pyrene, o-toluidine,
and excretion of mutagenic material in 24-h urine showed no sig-
niﬁcant group differences. However, a global group difference at
baseline was evident for exposure to 1,3-butadiene (Kruskal–Wal-
lis test p = 0.042).
All assessments of exposure to CO were signiﬁcantly decreased
in the EHCSS-K3 and EHCSS-K6 groups on Day 8, compared to
baseline. At Day 8, concentrations of COHb17:00, the primary end-
point, showed large and statistically signiﬁcant reductions in the
EHCSS-K3, EHCSS-K6, and no-smoking groups (all p < 0.001), a de-
crease in the Lark1 group (p < 0.01), and a slight increase in the M6J
group, compared to baseline (Fig. 2). Similarly, COHb concentra-
tions adjusted for the number of cigarettes smoked between
07:00 and 17:00 (COHb17:00/Ncig10) was statistically signiﬁcantly
decreased at Day 8 in the EHCSS-K3 and EHCSS-K6 groups (both
p < 0.001), and in the Lark1J group (p < 0.01), while a moderate in-
crease was observed in the M6J group, compared to baseline. The
change in COHb concentrations from 07:00 to 17:00
(DCOHb17:00–07:00) showed large and signiﬁcant decreases in the
EHCSS-K3, EHCSS-K6, and no-smoking groups (all p < 0.001), asmaller decrease in the Lark1 group (p < 0.01), and a slight increase
in the M6J group, compared to baseline. When adjusted for the
number of cigarettes smoked, DCOHb17:00–07:00/Ncig10 h concentra-
tions showed large and statistically signiﬁcant decreases in the
EHCSS-K3 and EHCSS-K6 groups (both p < 0.001), a smaller de-
crease in the Lark1 group (p < 0.01), and a slight increase in the
M6J group.
Signiﬁcant reductions (all p 6 0.001) in biomarkers of exposure
to 1,3-butadiene, 4-aminobiphenyl, acrolein, acrylamide, benzene,
crotonaldehyde, nicotine (determined as NEq, COT-P17:00, and NIC-
P17:00), NNK, pyrene, and o-toluidine, as well as excretion of muta-
genic material in urine were observed in the EHCSS-K3 and EHCSS-
K6 groups at Day 8, compared to baseline. Exposure to 2-naphthyl-
amine was also signiﬁcantly reduced in the EHCSS-K3 groups
(p < 0.01) and EHCSS-K6 (p < 0.05); however, many of the analyti-
cal measurements were below the LLOQ. Most biomarkers of expo-
sure, except for biomarkers of exposure to 1,3-butadiene and
crotonaldehyde as well as excretion of mutagenic material in urine,
were signiﬁcantly reduced (p 6 0.01) in the Lark1 group at Day 8,
compared to baseline. A signiﬁcant reduction in exposure to pyr-
ene (p < 0.001) and a signiﬁcant increase in exposure to crotonal-
dehyde (p < 0.05) were observed in the M6J group at Day 8,
compared to baseline. For the other biomarkers of exposure and
excretion of mutagenic material in urine there were no statistically
signiﬁcant changes in the M6J group, compared to baseline. The
largest reductions in biomarkers of exposure from baseline to
Day 8 were observed in the no-smoking group (all signiﬁcant at
the p 6 0.01 level). The observations were conﬁrmed after adjust-
ment for urinary creatinine excretion and the number of cigarettes
smoked per day in the smoking groups.
Nearly all comparisons by ANCOVA indicated statistically sig-
niﬁcant differences in biomarkers between the EHCSS-K3 and
EHCSS-K6 groups when compared to either the M6J or Lark1 study
groups on Day 8 (Table 5).
3.4. Safety evaluations
Nine subjects (7%) reported an AE after randomization (12 AE
episodes in total). None of the AEs were judged to be related to the
study cigarettes or study procedures. No trends related to study
groups were observed in AE reports, clinical laboratory, ECG, and
physical examinations. Themost commonly reported AEswere clin-
ical symptoms (2 episodes of dysmenorrhea in the M6J group) and
mild laboratory disorders (elevated alanine aminotransferase in
Table 4
Mean absolute biomarker levels and percentage change from Day 0 (baseline) to Day 8 per study group.
Smoke constituent biomarkera Study groupb,c
M6J EHCSS-K6 EHCSS-K3 Lark1 No-smoking
COHb17:00 (%)
e
Day 0 5.16 ± 1.81 5.04 ± 1.96 5.16 ± 1.61 4.46 ± 1.58 5.53 ± 1.63
Day 8 5.41 ± 1.86 2.07 ± 0.48 2.21 ± 0.63 3.75 ± 1.42 1.71 ± 0.32
Percentage change 7.2 ± 20.5% 53.7 ± 17.7%*** 56.2 ± 10.5%*** 14.8 ± 19.0%** 67.2 ± 9.1%***
COHbNcig10 h (%)
Day 0 0.49 ± 0.12 0.48 ± 0.13 0.50 ± 0.12 0.44 ± 0.15 0.54 ± 0.12
Day 8 0.52 ± 0.13 0.22 ± 0.09 0.21 ± 0.07 0.38 ± 0.14 –
Percentage change 10.5 ± 20.2%* 52.8 ± 18.8%*** 58.3 ± 11.6%*** 13.6 ± 17.7%** –
DCOHb17:00–07:00 (%)
Day 0 1.79 ± 1.07 1.60 ± 1.18 1.78 ± 0.85 1.44 ± 1.05 1.95 ± 0.92
Day 8 1.97 ± 1.20 0.04 ± 0.41 0.11 ± 0.53 0.95 ± 1.05 0.13 ± 0.35
Absolute mean change 0.17 ± 0.83% 1.57 ± 1.23%*** 1.69 ± 0.73%*** 0.49 ± 0.85%** 2.08 ± 0.93%***
DCOHb17:00–07:00/Ncig10 h (%)
Day 0 0.16 ± 0.08 0.14 ± 0.09 0.17 ± 0.06 0.13 ± 0.09 0.19 ± 0.08
Day 8 0.18 ± 0.09 0.00 ± 0.05 0.01 ± 0.06 0.09 ± 0.11 –
Absolute mean change 0.02 ± 0.08% 0.14 ± 0.09%*** 0.16 ± 0.07%*** 0.05 ± 0.07%** –
NEq (mg/24 h)
Day 0 9.55 ± 4.32 8.93 ± 5.56 8.94 ± 4.29 7.44 ± 3.86 9.29 ± 5.28
Day 8 9.62 ± 4.63 5.11 ± 3.37 3.89 ± 2.00 5.29 ± 3.56 0.21 ± 0.60
Percentage change 2.7 ± 29.0% 39.4 ± 32.7%*** 54.7 ± 21.3%*** 27.6 ± 26.2%*** 97.6 ± 6.5%***
NEqNcig24 h (mg)
Day 0 0.52 ± 0.16 0.48 ± 0.24 0.52 ± 0.20 0.43 ± 0.23 0.52 ± 0.21
Day 8 0.54 ± 0.20 0.27 ± 0.16 0.21 ± 0.10 0.29 ± 0.17 –
Percentage change 6.5 ± 32.8% 40.1 ± 28.5%*** 56.9 ± 23.4%*** 26.6 ± 28.2%*** –
COT-P17:00 (ng/ml)
Day 0 187.0 ± 97.5 197.5 ± 113.8 194.8 ± 104.1 177.3 ± 103.2 210.4 ± 101.5
Day 8 177.9 ± 99.9 111.2 ± 71.1 79.5 ± 48.3 116.2 ± 80.4 7.4 ± 9.6
Percentage change 0.6 ± 28.5% 43.7 ± 21.6%*** 60.3 ± 15.5%*** 34.2 ± 21.1%*** 95.7 ± 5.6%***
NIC-P17:00 (ng/ml)
Day 0 19.3 ± 10.4 18.4 ± 10.9 18.3 ± 9.1 16.3 ± 9.4 19.0 ± 7.2
Day 8 19.0 ± 9.5 10.1 ± 5.9 8.1 ± 5.9 11.0 ± 7.4 0.5 ± 0.00
Percentage change 8.2 ± 33.8% 42.9 ± 28.8%*** 56.1 ± 23.2%*** 30.0 ± 35.0%** 96.9 ± 1.4%***
MHBMA (lg/24 h)
Day 0 1.35 ± 1.24 2.08 ± 1.72 1.43 ± 1.06 1.37 ± 1.25 3.01 ± 3.22
Day 8 1.52 ± 1.36 0.74 ± 0.56 0.66 ± 0.69 1.23 ± 1.22 0.44 ± 0.32
Percentage change 16.2 ± 36.8% 55.3 ± 21.9%*** 49.5 ± 20.6%*** 8.8 ± 23.4% 63.5 ± 51.8%**
2-NA (ng/24 h)
Day 0 28.9 ± 46.0 23.7 ± 43.7 27.4 ± 43.3 20.9 ± 32.2 40.8 ± 45.1
Day 8 27.2 ± 41.5 6.9 ± 9.6 6.1 ± 3.7 15.2 ± 20.8 5.9 ± 3.9
Percentage change 14.3 ± 48.4 14.6 ± 51.8%* 9.8 ± 60.0%** 5.9 ± 23.7%* 13.7 ± 90.9%**
4-ABP (ng/24 h)
Day 0 15.2 ± 9.9 14.2 ± 10.9 14.6 ± 9.2 11.9 ± 7.0 15.2 ± 8.6
Day 8 15.0 ± 9.2 4.2 ± 1.8 3.9 ± 1.0 8.6 ± 5.4 4.6 ± 1.9
Percentage change 11.9 ± 38.2% 48.6 ± 58.8%*** 53.4 ± 46.5%*** 23.5 ± 26.9%*** 55.3 ± 39.6%***
3-HPMA (mg/24 h)
Day 0 1.46 ± 0.61 1.49 ± 0.69 1.46 ± 0.70 1.25 ± 0.45 1.68 ± 0.97
Day 8 1.37 ± 0.61 1.09 ± 0.51 1.01 ± 0.36 0.93 ± 0.36 0.48 ± 0.15
Percentage change 5.2 ± 18.8% 24.2 ± 22.1%*** 23.1 ± 27.4%*** 23.4 ± 18.8%*** 62.5 ± 19.9%***
AAMA (lg/24 h)
Day 0 119.2 ± 56.9 112.9 ± 44.3 112.4 ± 52.1 102.0 ± 39.3 122.2 ± 69.9
Day 8 118.9 ± 67.1 78.3 ± 31.9 67.7 ± 19.8 85.8 ± 36.1 61.6 ± 22.2
Percentage change 23.7 ± 144.1% 27.8 ± 21.6%*** 34.7 ± 18.7%*** 13.0 ± 25.4%** 36.2 ± 39.5%**
S-PMA (lg/24 h)
Day 0 1.94 ± 1.35 2.60 ± 1.77 1.91 ± 1.05 2.06 ± 1.71 3.54 ± 3.22
Day 8 2.24 ± 1.71 0.57 ± 0.57 0.48 ± 0.28 1.76 ± 1.72 0.34 ± 0.23
Percentage change 9.1 ± 31.4% 75.6 ± 11.4%*** 71.0 ± 13.0%*** 17.2 ± 23.5%* 85.3 ± 10.7%**
3-HMPMA (mg/24 h)
Day 0 1.11 ± 0.51 1.17 ± 0.51 1.11 ± 0.56 1.04 ± 0.40 1.32 ± 0.91
Day 8 1.28 ± 0.58 0.63 ± 0.15 0.61 ± 0.17 0.98 ± 1.00 0.47 ± 0.11
Percentage change 23.2 ± 44.6%* 41.2 ± 16.5%*** 38.3 ± 22.7%*** 6.7 ± 144.4% 53.3 ± 20.7%**
Total NNAL (ng/24 h)
Day 0 217 ± 126 220 ± 165 223 ± 131 189 ± 110 237 ± 192
Day 8 216 ± 122 100 ± 65 102 ± 48 148 ± 82 83 ± 82
Percentage change 1.2 ± 26.5% 51.5 ± 13.9%*** 52.6 ± 10.5%*** 17.2 ± 19.8%*** 65.4 ± 11.5%***
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Table 4 (continued)
Smoke constituent biomarkera Study groupb,c
M6J EHCSS-K6 EHCSS-K3 Lark1 No-smoking
Total 1-OHP (ng/24 h)
Day 0 175.2 ± 80.1 181.4 ± 103.2 191.5 ± 132.7 156.4 ± 73.4 174.7 ± 77.6
Day 8 135.3 ± 61.6 56.0 ± 28.4 59.0 ± 35.3 95.1 ± 40.3 42.0 ± 15.3
Percentage change 20.4 ± 21.4%*** 66.7 ± 14.8%*** 66.7 ± 14.8%*** 34.6 ± 19.7%*** 72.4 ± 13.0%***
o-TOL (ng/24 h)
Day 0 118.0 ± 56.8 106.1 ± 59.4 111.9 ± 58.9 92.8 ± 36.4 111.5 ± 49.7
Day 8 103.9 ± 59.0 31.1 ± 17.0 27.7 ± 12.9 65.0 ± 32.2 33.8 ± 23.6
Percentage change 9.1 ± 29.3% 68.4 ± 15.1%*** 73.0 ± 15.1%*** 28.7 ± 28.3%*** 64.6 ± 29.6%***
Mutagenicity (rev/24 h)d
Day 0 16875 ± 12709 17866 ± 12619 17939 ± 12036 15705 ± 8050 21231 ± 11424
Day 8 16897 ± 10707 7089 ± 3342 8842 ± 9177 13806 ± 7854 5879 ± 2941
Percentage change 10.8 ± 38.8% 41.5 ± 47.8%*** 31.0 ± 98.5%*** 7.4 ± 30.8% 69.7 ± 18.6%***
a Smoke constituent biomarkers abbreviated as: 1-OHP, 1-hydroxypyrene; 3-HMPMA, 3-hydroxy-1-methylpropyl mercapturic acid; 2-NA, 2-naphthylamine; 3-HPMA, 3-
hydroxypropyl mercapturic acid; 4-ABP, 4-aminobiphenyl; AAMA, acrylamide mercapturic acid; COHb17:00, carboxyhemoglobin at 17:00; DCOHb17:00–07:00, difference in
COHb from 07:00 to 17:00;DCOHb17:00–07:00/Ncig10 h, difference in COHb from 07:00 to 17:00 corrected for number of cigarettes smoked; COT-P17:00, plasma cotinine at 17:00;
GAMA, glycidamide mercapturic acid; MHBMA, monohydroxybutenyl mercapturic acid; NEq, nicotine equivalents; NNAL, NIC-P17:00, plasma nicotine at 17:00; 4-(methyl-
nitrosamino)-1-(3-pyridyl)-1-butanol; S-PMA, S-phenyl mercapturic acid; and o-TOL, o-toluidine.
b At Day 0 (baseline) all groups smoked the M6J cigarette. On Day 1 through Day 8 groups smoked their randomized study cigarette or stopped smoking.
c Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 series-K non-menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); EHCSS-K6, EHCSS
series-K heater and EHCSS-K6 series-K non-menthol cigarette (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO); M6J,Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and
7.0 mg CO); Lark1, Lark One non-menthol cigarette (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO); and No-smoking, smoking cessation group.
d Rev, revertants.
e Primary objective.
* Signiﬁcant change within group from Day 0 to Day 8 (p-value from two-sided paired sample t-test: p < 0.05.
** Signiﬁcant change within group from Day 0 to Day 8 (p-value from two-sided paired sample t-test: p < 0.01.
*** Signiﬁcant change within group from Day 0 to Day 8 (p-value from two-sided paired sample t-test p < 0.001.
Fig. 2. Percentage carboxyhemaglobin saturation (% COHb17:00) by group and study day.
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elevated aspartate aminotransferase in one subject on the EHCSS-K3
group, elevated blood total bilirubin in one subjects in both the
Lark1 and no-smoking groups, elevated white blood cell count in
one subjects in both the Lark1 and no-smoking groups, and in-
creased white blood cells in the urine of one subject in the EHCSS-
K6 group). A general tendency towards increased pulse rate, systolic
and diastolic bloodpressure, and decreased bodyweightwere noted
in all study groups; however, changes were judged to be without
clinical signiﬁcance. There were no withdrawals due to an AE, and
no occurrence of a serious adverse event.4. Discussion
The reported study of adult smokers in a controlled clinical
environment was conducted to evaluate changes in biomarkers
of exposure to selected cigarette smoke HPHC and excretion of
mutagenic material in urine occurring after switching from a con-
ventional lit-end non-menthol cigarette (M6J) to smoke either one
of two EHCSS series-K non-menthol cigarettes, or to smoke a con-
ventional lit-end non-menthol cigarette of lower tar and nicotine
yield (Lark1), or to no-smoking. A randomized, controlled, study
design was used to minimize bias and variability. A series of bio-
Table 5
Comparison between study cigarettes by ANCOVA (baseline-adjusted means on Day 8).
Smoke constituent biomarkera Comparisonb,c
EHCSS-K6 vs. M6J EHCSS-K6 vs. Lark1 EHCSS-K3 vs. M6J EHCSS-K3 vs. Lark1
COHb17:00 (%)e 3.27 (0.27)⁄⁄⁄ 1.98 (0.27)⁄⁄⁄ 3.22 (0.25)⁄⁄⁄ 2.00 (0.25)⁄⁄⁄
DCOHb17:00–07:00 (%) 1.83 (0.21)⁄⁄⁄ 1.00 (0.21)⁄⁄⁄ 1.87 (0.20) ⁄⁄⁄ 1.08 (0.20)⁄⁄⁄
NEq (mg/24 h) 4.02 0.66) ⁄⁄⁄ 1.16 (0.67) 5.28 (0.70)⁄⁄⁄ 2.35 (0.71)⁄⁄
COT-P17:00 (ng/ml) 77.91 (11.37)⁄⁄⁄ 19.13 (11.27) 107.38 (12.36)⁄⁄⁄ 48.25 (12.32)⁄⁄⁄
NIC-P17:00 (ng/ml) 8.60 (1.37)⁄⁄⁄ 2.22 (1.36) 10.28 (1.40)⁄⁄⁄ 4.02 (1.40)⁄⁄⁄
MHBMA (lg/24 h) 1.22 (0.18)⁄⁄⁄ 0.94 (0.18)⁄⁄⁄ 0.90 (0.14)⁄⁄⁄ 0.61 (0.14)⁄⁄⁄
2-NA (ng/24 h) 11.75 (3.93)⁄⁄ 7.24 (3.76) 14.35 (4.72)⁄⁄ 9.65 (4.55)⁄
4-ABP (ng/24 h) 9.04 (1.34)⁄⁄⁄ 4.97 (1.28)⁄⁄⁄ 9.12 (1.32)⁄⁄⁄ 5.24 (1.27)⁄⁄⁄
3-HPMA (mg/24 h) 0.23 (0.08)⁄⁄ 0.00 (0.08) 0.36 (0.08)⁄⁄⁄ 0.04 (0.08)
AAMA (lg/24 h) 35.42 (8.98) ⁄⁄⁄ 14.95 (8.94) 47.47 (9.17) ⁄⁄⁄ 25.02 (9.11)⁄⁄
S-PMA (lg/24 h) 2.11 (0.24)⁄⁄⁄ 1.56 (0.24)⁄⁄⁄ 1.83 (0.21)⁄⁄⁄ 1.32 (0.20)⁄⁄⁄
3-HMPMA (mg/24 h) 0.65 (0.17)⁄⁄⁄ 0.39 (0.17)⁄ 0.68 (0.18)⁄⁄⁄ 0.42 (0.18)⁄
Total NNAL (ng/24 h) 115.53 (13.33)⁄⁄⁄ 65.50 (13.26)⁄⁄⁄ 119.39 (12.99)⁄⁄⁄ 70.49 (13.02)⁄⁄⁄
Total 1-OHP (ng/24 h) 82.11 (8.44)⁄⁄⁄ 48.91 (8.40)⁄⁄⁄ 83.52 (9.16)⁄⁄⁄ 49.70 (9.18)⁄⁄⁄
o-TOL (ng/24 h) 66.35 (8.13)⁄⁄⁄ 39.90 (8.07)⁄⁄⁄ 77.41 (8.56)⁄⁄⁄ 49.81 (8.71)⁄⁄⁄
Mutagenicity (rev/24 h)d 43.2 (6.5)⁄⁄⁄ 34.0 (6.5)⁄⁄⁄ 40.1 (7.7)⁄⁄⁄ 31.1 (7.7)⁄⁄⁄
a Smoke constituent biomarkers abbreviated as: 1-OHP, 1-hydroxypyrene; 3-HMPMA, 3-hydroxy-1-methylpropyl mercapturic acid; 2-NA, 2-naphthylamine; 3-HPMA, 3-
hydroxypropyl mercapturic acid; 4-ABP, 4-aminobiphenyl; AAMA, acrylamide mercapturic acid; COHb17:00, carboxyhemoglobin at 17:00; DCOHb17:00–07:00, difference in
COHb from 07:00 to 17:00;DCOHb17:00–07:00/Ncig10 h, difference in COHb from 07:00 to 17:00 corrected for number of cigarettes smoked; COT-P17:00, plasma cotinine at 17:00;
GAMA, glycidamide mercapturic acid; MHBMA, monohydroxybutenyl mercapturic acid; NEq, nicotine equivalents; NNAL, NIC-P17:00, plasma nicotine at 17:00; 4-(methyl-
nitrosamino)-1-(3-pyridyl)-1-butanol; S-PMA, S-phenyl mercapturic acid; and o-TOL, o-toluidine.
b Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 series-K non-menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); EHCSS-K6, EHCSS
series-K heater and EHCSS-K6 series-K non-menthol cigarette (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO); M6J,Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and
7.0 mg CO); and Lark1, Lark One non-menthol cigarette (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO).
c Least squares mean (SE) and Bonferoni-corrected p-value according to Dunnett: ⁄p < 0.05; ⁄⁄p < 0.01; ⁄⁄⁄p < 0.001.
d Rev, revertants.
e Primary objective.
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cigarette smoke HPHC were investigated (Table 1). Cigarette smoke
HPHC were selected based on the availability of validated methods
of analysis for the respective biomarkers of exposure. Controlled
‘switching’ was used to maintain a fairly constant number of ciga-
rettes smoked per day (Table 3) and to minimize the effects of
compensation on switching to a cigarette of lower tar and nicotine
yield (Scherer, 1999). Based on excretion of NEqNCig at Day 8 com-
pared to baseline (Table 5), smokers of M6J cigarettes who
switched to the Lark1 cigarette showed an average compensation
of 67% of the difference in nicotine yield,1 while subjects who
switched to either EHCSS-K3 or EHCSS-K6 cigarettes showed negligi-
ble compensation (5% and 0%, respectively). Similarly, in a separate
study (Tricker et al., 2012a), Caucasian smokers who switched from
smoking the Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nico-
tine, and 7.0 mg CO) to use the current third-generation EHCSS ser-
ies-K heater with EHCSS-K3 or EHCSS-K6 non-menthol cigarettes
also showed negligible compensation (1% and 4%, respectively),
while switching to a lower tar and nicotine delivery cigarette
(1 mg tar, 0.1 mg nicotine) resulted in an average compensation of
57% of the difference in nicotine yield.
The observed reductions in COHb17:00, the primary endpoint of
the study, at Day 8 (Table 4) are consistent with other studies
investigating reductions in exposure to CO in smokers who
switched to using previous generations of the EHCSS heater to
smoke EHCSS non-menthol cigarettes (Buchhalter and Eissenberg,
2000; Buchhalter et al., 2001; Hughes and Keely, 2004; Roethig
et al., 2005, 2007), and the current EHCSS series-K heater and the
EHCSS series-K non-menthol cigarette (Frost-Pineda et al., 2008a;
Martin Leroy et al., 2012; Tricker et al., 2012a,b). Reductions in
COHb concentrations have also been observed in smokers who
switched from a conventional lit-end menthol cigarette to use
the third-generation EHCSS series-K heater with a series-K men-
thol cigarette (Tricker et al., 2012c).1 Compensation = 1  [% Change in NEq per cigarette/% Change of cigarette ISO
nicotine yield].Signiﬁcant reductions in tobacco-speciﬁc biomarkers of expo-
sure (nicotine metabolites and total NNAL) were observed in the
EHCSS-K3, EHCSS-K6, Lark1, and no-smoking groups (all
p 6 0.001), but not in the M6J group at Day 8, compared to base-
line. The reductions in exposure to nicotine, determined as excre-
tion of NEq in urine, were conﬁrmed by measurement of COT-
P17:00 and NIC-P17:00 (Table 4). Non-speciﬁc tobacco-related bio-
markers of exposure to 1,3-butadiene, 2-naphthylamine, 4-amino-
biphenyl, acrolein, acrylamide, benzene, crotonaldehyde, pyrene,
and o-toluidine also showed signiﬁcant reductions in smokers of
the M6J cigarette who switched to either the EHCSS-K3 or
EHCSS-K6 cigarettes at Day 8, compared to baseline. Reductions
in exposure to acrylamide, determined using excretion of acrylam-
ide mercapturic acid (AAMA) in urine, were further conﬁrmed by
quantitatively similar trends in reduction of glycidamide mercap-
turic acid (GAMA) excretion (data not shown).
Switching from smoking the M6J cigarette to using the EHCSS
series-K heater to smoke either the EHCSS-K3 or the EHCSS-K6 cig-
arette, or switching to no-smoking, resulted in statistically signiﬁ-
cant reductions (p < 0.001) in excretion of mutagenic material in
urine, detected by using tester strain Salmonella typhimurium
YG1024 (Einistö et al., 1990), at Day 8, compared to baseline
(Table 4). Similar observations have been reported in previous clin-
ical evaluations of earlier generations of the EHCSS heater and
smoking EHCSS non-menthol cigarettes (Roethig et al., 2005,
2007) and the current third-generation EHCSS series-K heater
and smoking series-K non-menthol cigarettes (Frost-Pineda et al.,
2008a: Tricker et al., 2012a,b). Salmonella typhimurium YG1024,
an o-acetyltransferase-overproducing derivative of tester strain
TA98, is sensitive to the mutagenic activity of aromatic amino,
hydroxylamino, and nitro compounds present in urine (Einistö
et al., 1990). Although the mainstream cigarette smoke HPHC
responsible for excretion of mutagenic material in urine are un-
known, 2-naphthylamine, 4-aminobiphenyl, and o-toluidine were
selected as representative aromatic amino compounds present in
cigarette smoke for which validated methods of analysis were
available. In parallel with the reduced excretion of mutagenic
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amine (p 6 0.05), and 4-aminobiphenyl and o-toluidine (both
p < 0.001) were observed in the EHCSS-K3, EHCSS-K6, Lark1, and
no-smoking groups at Day 8, compared to baseline.
Comparisons of COHb17:00 and DCOHb17:00–07:00 at Day 8 be-
tween the EHCSS-K6 and M6J or Lark1 groups, and between the
EHCSS-K3 and M6J or Lark1 groups, showed statistically signiﬁcant
between-group differences (p < 0.001), with lower values for the
EHCSS-K6 and EHCSS-K3 groups (Table 5). Similarly, comparisons
of biomarkers of exposure to 1,3-butadiene, 4-aminobiphenyl, ben-
zene, NNK, pyrene, o-toluidine, and excretion of mutagenic mate-
rial in urine at Day 8 between the EHCSS-K6 and M6J or Lark1
groups, and between the EHCSS-K3 and M6J or Lark1 groups,
showed statistically signiﬁcant between-group differences
(p < 0.001), with lower values for the EHCSS-K6 and EHCSS-K3
groups. Comparisons of biomarkers of exposure to acrylamide, cro-
tonaldehyde, and nicotine (determined as NEq, COT-P17:00 and NIC-
P17:00) at Day 8 between the EHCSS-K6 and M6J groups, and be-
tween the EHCSS-K3 and M6J groups showed, statistically signiﬁ-
cant between-group differences (p < 0.001), with lower values in
the EHCSS-K6 and EHCSS-K3 groups. Comparisons of the bio-
marker of exposure to 2-naphthylamine at Day 8 between the
EHCSS-K6 and M6J groups, and between the EHCSS-K3 and M6J
groups, showed statistically signiﬁcant between-group differences
(p < 0.01), with lower values in the EHCSS-K6 and EHCSS-K3
groups. While the comparisons of biomarkers of exposure to nico-
tine (determined as NEq, COT-P17:00 and NIC-P17:00) at Day 8 be-
tween the EHCSS-K3 and Lark1 groups showed statistically
signiﬁcant between-group differences (p < 0.01), with lower values
in the EHCSS-K3 group, the comparisons between the EHCSS-K6
and Lark1 groups failed to reach statistical signiﬁcance. Compari-
sons of biomarkers of exposure to crotonaldehyde at Day 8 be-
tween the EHCSS-K6 and Lark1 groups and between the EHCSS-
K3 and Lark1 groups showed statistically signiﬁcant between-
group differences (p < 0.05), with lower values in the EHCSS-K6
and EHCSS-K3 groups. Comparisons of acrolein and acrylamide at
Day 8 in the EHCSS-K6 and Lark1 groups, and acrolein at Day 8
in the EHCSS-K3 and Lark1 groups failed to reach statistical
signiﬁcance.
Despite the short duration of conﬁnement in the current study,
statistically signiﬁcant changes in biomarkers of exposure to sev-
eral selected cigarette smoke HPHC representing different classes
of chemical compounds were observed (Table 4). Although expo-
sure to 2-naphthylamine and 4-aminobiphenyl were signiﬁcantly
reduced, many of the analytical measurements were below the
LLOQ values (even prior to randomization), resulting in the need
to use substituted data (LLOQ/2) in the statistical evaluations. Sig-
niﬁcant reductions in exposure to acrylamide and crotonaldehyde
were observed in most study groups; however, some doubt exists
as to the speciﬁcity of the biomarkers used to determine exposure
to acrolein (Stevens and Maier, 2008) and crotonaldehyde (Hecht
et al., 2001). The results of this study cannot be extrapolated to
predict the long-term effects of switching from a conventional
lit-end cigarette to use an EHCSS series-K heater and EHCSS ciga-
rette on reductions in exposure to cigarette smoke HPHC as real-
life non-conﬁned studies with uncontrolled switching demonstrate
that increased consumption of EHCSS cigarettes may occur (Frost-
Pineda et al., 2008b; Martin Leroy et al., 2012).
In summary, this study shows statistically signiﬁcant mean
reductions in biomarkers of exposure to selected cigarette smoke
HPHC and excretion of mutagenic material in urine of smokers
who smoke the M6J cigarette and switch to use the EHCSS
lighter and smoke either the EHCSS-K3 or the EHCSS-K6
cigarette (9.8 ± 60.0% to 73.0 ± 15.1% and 14.6 ± 51.8% to
75.6 ± 11.4%, respectively; all p 6 0.05) at Day 8, compared to
baseline. In smokers who switch to smoke the Lark1 cigarette, aconventional lit-end cigarette representative of the low-tar ciga-
rette market, smaller mean reductions (4.2 ± 24.1% to
39.4 ± 17.5%) were observed, most of which were statistically sig-
niﬁcant (p 6 0.05). The largest mean reductions (13.7 ± 90.9% to
97.6 ± 6.5%; all p 6 0.01) occurred in smokers who switched to
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